Search research articles
Contact Us
Filters
Showing results (311-320 of 346) with videos related to
Page
of 35
Sort By:
Blood Cancer Journal
|
April 2, 2025
VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial
Mahesh Swaminathan, Courtney D DiNardo, Abhishek Maiti, et al.
Blood Cancer Journal
|
February 10, 2021
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
Abhishek Maiti, Courtney D DiNardo, Naval G Daver, et al.
Cancer
|
June 14, 2017
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens
Rashmi Kanagal-Shamanna, Preetesh Jain, Koichi Takahashi, et al.
American Journal of Hematology
|
March 15, 2020
Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia
Koji Sasaki, Hagop Kantarjian, William Wierda, et al.
Cancer
|
April 1, 2021
Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia
Caitlin R Rausch, Courtney D DiNardo, Abhishek Maiti, et al.
Leukemia
|
March 12, 2026
Immunophenotypic changes following menin inhibition in acute myeloid leukemia
Sanam Loghavi, Aziz Farhat, Trevor J Jamison, et al.
Journal of Hematology & Oncology
|
July 8, 2023
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
Nicholas J Short, Muharrem Muftuoglu, Faustine Ong, et al.
American Journal of Hematology
|
September 2, 2022
Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment
Curtis A Lachowiez, Patrick K Reville, Hagop Kantarjian, et al.
Blood Cancer Discovery
|
March 8, 2021
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors
Ahmad S Alotaibi, Musa Yilmaz, Rashmi Kanagal-Shamanna, et al.
Journal of Hematology & Oncology
|
October 9, 2020
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
Musa Yilmaz, Mansour Alfayez, Courtney D DiNardo, et al.
Page
of 35
Search research articles
Search
Showing results (311-320 of 346) with videos related to
Sort By:
Page
of 35
Blood Cancer Journal
|
April 2, 2025
VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial
Mahesh Swaminathan, Courtney D DiNardo, Abhishek Maiti, et al.
Blood Cancer Journal
|
February 10, 2021
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
Abhishek Maiti, Courtney D DiNardo, Naval G Daver, et al.
Cancer
|
June 14, 2017
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens
Rashmi Kanagal-Shamanna, Preetesh Jain, Koichi Takahashi, et al.
American Journal of Hematology
|
March 15, 2020
Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia
Koji Sasaki, Hagop Kantarjian, William Wierda, et al.
Cancer
|
April 1, 2021
Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia
Caitlin R Rausch, Courtney D DiNardo, Abhishek Maiti, et al.
Leukemia
|
March 12, 2026
Immunophenotypic changes following menin inhibition in acute myeloid leukemia
Sanam Loghavi, Aziz Farhat, Trevor J Jamison, et al.
Journal of Hematology & Oncology
|
July 8, 2023
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
Nicholas J Short, Muharrem Muftuoglu, Faustine Ong, et al.
American Journal of Hematology
|
September 2, 2022
Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment
Curtis A Lachowiez, Patrick K Reville, Hagop Kantarjian, et al.
Blood Cancer Discovery
|
March 8, 2021
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors
Ahmad S Alotaibi, Musa Yilmaz, Rashmi Kanagal-Shamanna, et al.
Journal of Hematology & Oncology
|
October 9, 2020
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
Musa Yilmaz, Mansour Alfayez, Courtney D DiNardo, et al.
Page
of 35